China issues 15th Five-Year Plan to boost drug R&D with AI and quantum tech
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 18, China's Ministry of Industry and Information Technology (MIIT) and nine other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan calls for accelerating the deployment of frontier technologies to empower drug research and development, specifically naming artificial intelligence, quantum computing, supercomputing, and computational medicine. It also encourages exploring novel production models for pharmaceuticals and medical devices, including ultra-limit manufacturing, space-based pharmaceutical manufacturing, and biomanufacturing. Additionally, the plan aims to deepen the application of gene editing, precise molecular delivery, cell programming, advanced omics, and next-generation brain-computer interfaces. Key technological breakthroughs are targeted in areas such as synthetic artificial life systems, organoids, universal cell therapies, complex regenerative organs, theranostic radiopharmaceuticals, and xenotransplantation organs, with the goal of cultivating new growth drivers for the industry.
Source report
Beijing, September 18 (Cailian Press) — The Ministry of Industry and Information Technology (MIIT), together with nine other government departments, has jointly released the "15th Five-Year Plan for the Development of the Pharmaceutical Industry."
The plan outlines a strategic push to accelerate the deployment of frontier technologies and products in the pharmaceutical sector. Key highlights include:
- Strengthening interdisciplinary integration and the supply of cutting-edge technologies.
- Supporting joint research among pharmaceutical enterprises, universities, scientific research institutes, and medical institutions.
- Accelerating drug R&D through new technologies such as:
- Artificial intelligence
- Quantum computing
- Supercomputing
- Computational medicine
- Exploring new production models for drugs and medical devices, including:
- Ultra-limit manufacturing
- Space-based pharmaceutical manufacturing
- Biomanufacturing
- Deepening the application of frontier technologies such as:
- Gene editing
- Precise molecular delivery
- Cell programming and regulation
- Advanced omics
- Next-generation brain-computer interfaces
- Achieving breakthroughs in key technologies, including:
- Synthetic artificial life systems
- Organoids and organ-on-a-chip
- Universal cell therapies
- Complex regenerative organs
- Theranostic radiopharmaceuticals
- Xenotransplantation organs
The plan aims to cultivate several new growth drivers for the pharmaceutical industry, positioning it for long-term innovation and global competitiveness.
Source
财联社Eastern
Part of this Story
China’s 15th Five-Year Plan targets 25% global share of first-in-class drugs by 2030